This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Insider Trading Alert - Sherwin-Williams Company And 4 Others Traded By Insiders

Stock quotes in this article: SHW, HON, ED, UTHR, WOR

United Therapeutics Corporation (UTHR) - FREE Research Report

Causey Christopher who is Director at UTD THERAPEUTIC bought 3,450 shares at $32.50 per share for a total value of $146,250.00 on July 5, 2013. Following this transaction, the Director owned 3,416 shares meaning that the stake was boosted by 116.32% with the 3,450 share acquisition.

Jeffs Roger who is President & COO at UTD THERAPEUTIC bought 26,773 shares at $30.84 per share for a total value of $925,250.00 on July 5, 2013. Following this transaction, the President & COO owned 56,293 shares meaning that the stake was boosted by 54.07% with the 26,773 share acquisition.

Rothblatt Martine A who is CEO at UTD THERAPEUTIC bought 716,564 shares at $25.46 per share for a total value of $393,409.08 on July 5, 2013. Following this transaction, the CEO owned 712,981 shares meaning that the stake was boosted by 17295.78% with the 716,564 share acquisition.

The shares most recently traded at $67.97, down $0.17, or 0.25% since the insider transactions. Historical insider transactions for United Therapeutics Corporation go as follows:

  • 24-Week # shares sold: 7,666

The average volume for United Therapeutics Corporation has been 676,800 shares per day over the past 30 days. United Therapeutics Corporation has a market cap of $3.3 billion and is part of the health care sector and drugs industry. Shares are up 25.81% year to date as of the close of trading on Monday.

United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. The company has a P/E ratio of 10.7. Currently there are 3 analysts that rate United Therapeutics Corporation a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UTHR - FREE

TheStreet Quant Ratings rates United Therapeutics Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, attractive valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full United Therapeutics Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs